The Wayback Machine - https://web.archive.org/web/20220906081746/https://animal-diseases.efsa.europa.eu/LSDV
Skip to the contents
Disease profile
×
Reported cases
From
To
Disease situation (Filter animal category)
From
To

Geographical distribution

Based on official disease reports to the OIE

LSD is a disease listed in the World Organisation for Animal Health (OIE) Terrestrial Animal Health Code and must be reported to the OIE. The map to the right displays outbreak points reported to the OIE early warning system since 2005.

As described in the OIE Terrestrial Animal Health Code, the OIE early warning system includes immediate notifications and follow-up reports on:

  • First occurrences of a listed disease,
  • Recurrence of an eradicated listed disease,
  • First occurrences of new strain of a pathogenic agent of a listed disease,
  • Recurrence of an eradicated strain,
  • Sudden and unexpected changes in the distribution or increase in incidence or virulence of, or morbidity or mortality caused by the pathogenic agent of a listed disease
  • Occurrence of a listed disease in an unusual host species.

Countries are coloured according to the available information regarding their stable disease situation (disease status legend). This information is provided by countries through the OIE monitoring system, which is a different reporting channel.
Immediate notifications (points) and disease status (country/region colours) are reported to the OIE in different spatial and temporal scales, and therefore are displayed in the map as layers which can be filtered independently.

Last updated at: 2022-09-05

For more up to date reports, visit the original data source: OIE-WAHIS.

Disease

Animal Health Impact

A summary of the disease in animal hosts is given in the OIE Technical disease card.

The panel to the right summarizes all evidence collected by EFSA from published experimental infection studies describing the health effects of this pathogen in host animal species. Scroll down through the content.

Summaries of available scientific evidence are provided concerning:

  • Host species
  • Start of clinical signs (incubation period)
  • Duration of clinical signs
  • All diverse types of clinical signs reported in the different host species
  • Case fatality
  • Meta-analysis of the reported duration of observable clinical signs, accounting for censoring in the experimental infection study groups

EFSA conducts regular systematic literature reviews covering all experimental infections published in peer-reviewed literature in English since 1970.

You can download all data collected through systematic literature review here. Data fields are explained in this read-me file.

*The review was last updated in January 2021. The complete list of references is available for download here. If important references to primary studies are missing, contact animal-diseases@efsa.europa.eu. The full review protocol can be downloaded here.

Public Health

Humans are not susceptible to LSDV and therefore there is no direct impact on public health OIE Technical disease card.

Agent

Virus taxonomy

Family: Poxviridae

Genus: Capripoxvirus

Species: Lumpy skin disease virus

Virus: lumpy skin disease virus (LSDV)

Virus characteristics

Refer to the OIE Technical disease card for a key summary of the virus characteristics.

Virus survival outside living hosts

The panel to the right summarizes all evidence collected by EFSA from published experiments on pathogen survival. Scroll down through the content.

Summaries of available scientific evidence are provided concerning:

  • Survival plots indicating the maximum number of days the virus was detected in different matrices under different conditions (temperature)
  • Half-life studies which documented virus viability decay over time under different temperatures
  • Meta-analysis of the reported virus survival period for matrices in which a sufficient number of studies were found

EFSA conducts regular systematic literature reviews covering pathogen survival experiments published in peer-reviewed literature in English since 1970.

You can download all data collected through systematic literature review here. Data fields are explained in this read-me file.

*The review was last updated in January 2021. The complete list of references is available for download here. If important references to primary studies are missing, contact animal-diseases@efsa.europa.eu. The full review protocol can be downloaded here.

Transmission

Refer to the OIE Technical disease card for a key summary of the disease transmission and epidemiological parameters.

Several arthropod species can act as mechanical vectors for LSDV.

The panel to the right summarizes all evidence collected by EFSA from published experimental infection studies describing host infectiousness. Scroll down through the content.

Summaries of available scientific evidence are provided concerning:

  • Evidence of Host-host transmission
  • Evidence of transplacentary transmission
  • Meta-analysis of the reported duration of the infectious period, accounting for censoring in the experimental infection study groups
  • Data for all animal matrices in which agent presence was demonstrated.

EFSA conducts regular systematic literature reviews covering all experimental infections published in peer-reviewed literature in English since 1970.

You can download all data collected through systematic literature review here. Data fields are explained in this read-me file.

*The review was last updated in January 2021. The complete list of references is available for download here. If important references to primary studies are missing, contact animal-diseases@efsa.europa.eu. The full review protocol can be downloaded here.

Diagnosis

OIE-prescribed tests for international trade include:the commercial double-antigen enzyme-linked immunosorbent assay (ELISA) and (real-time) polymerase chain reaction (PCR) excluding vaccine strains (OIE, Terrestrial Manual, Haegeman et al. 2020) and immunofluorescence tests or PCR.

EFSA conducts regular systematic literature reviews covering peer-reviewed literature in English since 1970, covering diagnostic tests aLSDoved for use in the European Union (EU).

Data were collected from all evaluations of performance of those tests which provided sensitivity or specificity (or enough data to estimate those needed to be provided). You can browse through the data collected scrolling the panel to the right.

Two main types of performance evaluation studies are reported in literature:

  • (i) those which evaluated test performance using a set of samples from animals with known infectious status (samples from truly infected and non-infected animals);
  • (ii) those which compared test performance against a gold standard test, assuming the result of that test (positive or negative) to represent true infection status.

Results for these two types of evaluations are presented separately.

We have chosen not to aggregate and summarize the results because the study conditions can vary greatly. Instead, we present below the results for all the articles retrieved from the literature individually, grouped by type of test and, when relevant, animal species.

You can download all data collected through systematic literature review here. Data fields are explained in this read-me file.

The review was last updated in January 2021. The complete list of references is available for download here. If important references to primary studies are missing, contact animal-diseases@efsa.europa.eu. The full review protocol can be downloaded here.

Vaccination

The use of LSD vaccines is regulated according to Regulation (EU) 2016/429 and Commission Implementing Regulation (EU) 2021/1070.

Control of LSD is regulated by Regulation (EU) 2016/429 of the European Parliament and of the Council of 9 March 2016 on transmissible animal diseases and amending and repealing certain acts in the area of animal health (‘Animal Health Law’). Special control measures for a limited period of time related to LSDV infection are also in place Commission Implementing Regulation (EU) 2021/1070.

EFSA conducts regular systematic literature reviews covering all vaccine efficacy studies published in peer-reviewed literature in English since 1970, when evaluating vaccines aLSDoved for use in the European Union. The next update of the SLR for vaccines is scheduled to be carried out in 2023.

Treatments

In accordance with the Animal Health Law (AHL) in the EU (see next tab) and the special control measures for LSDV infection Commission Implementing Regulation (EU) 2021/1070, movement of cattle is restricted in areas where LSDV is detected and/or where vaccinations occur.

Animal Health Law Risk Assessments

LSD is listed as a category A diseases in the "Animal Health Law" - Regulation (EU) 2016/429 of the European Parliament and of the Council of 9 March 2016 on transmissible animal diseases and amending and repealing certain acts in the area of animal health.

EFSA has published a series of Scientific Opinions on risk assessment of several scientific topics within the framework of AHL, upon request by the European Comission (EC). You can browse through the AHL legislations and EFSA’s Scientific Opinions on the right panel.

Acknowledgments

The CoVetLab consortium has been responsible for the systematic literature reviews since 2015, and has delivered story maps to EFSA since 2021. Partners are: Swedish National Veterinary Institute (SVA, Sweden); Wageningen Bioveterinary Research (WBVR, The Netherlands); Animal and Plant Health Agency (APHA; UK) and the University of Surrey (UK).

Geographical distribution data has been kindly provided by the World Organisation of Animal Health (OIE). OIE-WAHIS (OIE World Animal Health Information System) is the original source of these data.

EFSA thanks the following experts for their specific contribution to this story map:

  • Expert name1
  • Expert name2

Commission Implementing Regulation (EU) 2021/1070 of 28 June 2021 laying down special control measures for a limited period of time related to infection with lumpy skin disease virus

Dórea FC, Swanenburg M, van Roermund H, Horigan V, de Vos C, Gale P, Lilja T, Comin A, Bahuon C, Zientara S, Young B, Vial F, Kosmider R and Lindberg A, 2017. Data collection for risk assessments on animal health. EFSA supporting publication,14(1):EN-1171, 209 pp. doi: 10.2903/sp.efsa.2017.EN-1171.

Haegeman et al. 2020. Overview of diagnostic tools for Capripox virus infections. Prev Vet Med, 181, 104704

OIE (World Organisation for Animal Health) Technical Disease Card: Lumpy skin disease. 2021.

OIE (World Organisation for Animal Health), 2017. Lumpy Skind Diseases. Chapter 2.4.13. OIE Terrestrial Animal Health Manual. OIE, Paris, France

OIE (World Organisation for Animal Health), 2021. Infection with lumpy skin disease virus. Chapter 11.9. OIE Terrestrial Animal Health Code 2019. OIE, Paris, France

OIE (World Organisation for Animal Health). Terrestrial Animal Health Code 2021. OIE, Paris, France

OIE-WAHIS (OIE World Animal Health Information System)

Regulation (EU) 2016/429 of the European Parliament and of the Council of 9 March 2016 on transmissible animal diseases and amending and repealing certain acts in the area of animal health (‘Animal Health Law’)

Sprygin et al. 2019. Transmission of lumpy skin disease virus: A short review

Systematic Literature Review Protocol, COVETLAB consortium. Review Protocol 2021.

References

The list of references displayed in this storymap is available on the right panel.

You can also download the complete list of references for each of the seven specific knowledge domains for which EFSA carries out systematic literature reviews regularly (living reviews):